PERIPHERAL T CELL LYMPHOMA (PTCL) AND TREATMENT OUT‐COME SINGLE CENTRE RETROSPECTIVE STUDY

Abstract

Introduction: Mature T-cell lymphomas comprise 15% to 20% of all aggressive non-Hodgkin lymphomas (NHL) and 5% to 10% of all NHLs. Compared to their B-cell counterparts, PTCLs remain largely unexplored and the optimal treatment ill-defined due to disease rarity and biological heterogeneity. CHOP-type chemotherapy has been the mainstay of therapy for PTCL with some exception in NK/T cell lymphoma, but with the notable exception of ALK-positive ALCL, outcome has been uniformly disappointing3-5. For the main nodal PTCLs (AITL, PTCL-NOS, and ALK− ALCL), the 2- and 5-year progression-free survival (PFS) is approximately 35% and 25%, and the 2- and 5-year overall survival (OS) is 45% and 35%, respectively6-8. Progressions/relapses of PTCLs are frequent (approximately 70% of patients), occur most often early (during the first year after initial diagnosis), and have a poor outcome, with a median OS of approximately 6 months 9-11. Methods: Patients were identified through pathology database and informed consent obtained. Patient’s demographic characteristics, clinical features, initial / subsequent treatment and survival were analysed. Data cut-off was 31/01/2023. Results: Twenty-seven patients were included in this study, with male predominance (70%), the median age was 69 years (Rang 17-84 years) and the majority with advanced disease (67%). The common histology subtype was ALCL in 10 patients (37%) (Alk-Neg =7 & Alk-Pos =3) followed by PTCL in 9 patients (33%). While EATL, AITL subtypes were reported in 5(18%), 3(11%) patients respectively. Chemotherapy was the main initial treatment modality in our cohort (26 patients / 96%) (CHOP based /19 patients, CHOEP in 4 patients, and GDP based /3 patients) and 1patient (4%) was not suitable for any therapy. Complete response (CR) was achieved in 16 patients (59%) and 8 patients (30%) subsequently relapsed, while other treated patients (10/37%) experienced disease progression. At relapse GDP and Brentuximab Vedotin therapy were used for in 8 and 3 patients respectively resulted in CR in 2 patients and progression disease in the reminder. Autologous bone marrow transplant consolidation was used in 3 patients (10%), and radiotherapy was used in 5patients (15%). At time of study data analysis (31/01/2023), 8 patients (30%) were still alive and 19 patient (70%) had died mostly lymphoma related death (18 patients). Keywords: Aggressive T-cell non-Hodgkin lymphoma, Pathology and Classification of Lymphomas No conflicts of interests pertinent to the abstract.